UroGen Pharma URGN
NASDAQ URGN
$41.40 +0.85 (+2.10%)
At close: Oct 2, 2026 · 4:00 PM EDT

UroGen Pharma (URGN) Asset Writedowns and Impairment (2022)

Updated

UroGen Pharma's Asset Writedowns and Impairment came in at $255,000 for Q4 2022, down 27.1% from the prior quarter.

Analysis

UroGen Pharma (URGN) Asset Writedowns and Impairment (2022) Analysis & Trends

For FY2022, UroGen Pharma's Asset Writedowns and Impairment was $870,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 UroGen Pharma 2.02 Bn 1.53 Bn 65.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 255,000.00
Sep 30, 2022 350,000.00
API Access

UroGen Pharma Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=URGN&period=max&api_key=YOUR_API_KEY